Paclitaxel for Injection(Albumin-Bound)

Blockbuster drugs in tumor chemotherapy, simultaneous filing in China and Europe

Albumin-bound paclitaxel(Apexelsin) takes the advantage of nanotechnology to combine the drug substance with human albumin to generate nanoparticles with improved solubility, featured by "Three Highs and One Low", i.e. high dose, high distribution in tumor tissue, high efficacy, and low toxicity. Albumin-bound paclitaxel is recommended by the NCCN and CSCO guidelines for the treatment of breast cancer. It is the only product in China that is applied simultaneously in China, the United States, and the European Union and the NDA in China and European Union has been accepted for review.

Indications

Metastatic breast cancer after failure of combination chemotherapy or breast cancer within 6 months after adjuvant chemotherapy.

Recommended reading

Unlocking the Power of Albumin-Bound Paclitaxel: Quality, Affordability, and Innovation

Exploring the Power of Albumin-Bound Paclitaxel: A Breakthrough in Cancer Treatment